undamentalytics Newsletter
Sign in

Biomarin Pharmaceutical Inc income statement

In fiscal 2025, Biomarin Pharmaceutical Inc reported revenue of $3.22bn, up 12.9% on the year before, operating income of $409m (a 12.7% margin) and net income of $349m, or $1.80 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3253764415015487498901,1171,3141,4911,7041,8601,8462,0962,4192,8543,2213,407
Cost of revenue6670849288122152210242315359524471503532580717814
Gross profit2593063574094606277389071,0721,1761,3451,3361,3761,5931,8872,2742,5042,593
Research and development115147214302355462635662611696715628629650747747922988
Selling, general and administrative1241521751982353024024775546046817387598238921,0091,1531,368
Operating income161−34−110−156−93−111−803−15−124−100−43−82161186484409149
Interest expense1411881037383943442329151617131176
Income before tax1−21−44−118−177−125−155−831−36−143−95−49−75150189542482149
Income tax1−22710−4−0917−20181−65−71−903−1182111513476
Net income−0206−54−114−176−134−172−630−117−77−24854−6414216842734973
Diluted EPS$0.00$1.73−$0.48−$0.95−$1.28−$0.92−$1.07−$3.81−$0.67−$0.44−$0.13$4.50−$0.35$0.75$0.87$2.21$1.80$0.37
Diluted shares (average)100m126m112m120m138m146m160m166m174m177m179m192m183m189m192m197m197m197m
EBITDA37281−66−120−47−64−70773−2856226263290581489206

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BMRN vs BNTXBMRN vs UTHRBMRN vs NBIXARGX vs BMRN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Biomarin Pharmaceutical Inc's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Biomarin Pharmaceutical Inc.